ABSTRACT
BackgroundAs the increasing number of Corona Virus Disease 2019 (COVID-19) patients caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), which caused an outbreak initiated from Wuhan, China in December, 2019, the clinical features and treatment of COVID-19 patients have been understood. However, it is urgent to need the rapid and accurate detection for SARS-CoV-2 infection diagnosis. We aimed to evaluate the antibodies-based and nucleic acid-based tests (NAT) for SARS-CoV-2-infected patients. MethodWe retrospectively and observationally studied 133 patients diagnosed with SARS-CoV-2 and admitted in Renmin Hospital of Wuhan University, China, from Feb 17 to Mar 1, 2020. Demographic data, symptoms, clinical examination, laboratory tests, and clinical outcomes were collected. Data were compared between IgM-IgG antibody test and real-time RT-PCR detection for COVID-19 patients. ResultsOf 133 patients with SARS-CoV-2 infection, there were 44 moderate cases, 52 severe cases, and 37 critical cases with no significant difference of gender and age among three subgroups. Overall, the positive ratio in IgM antibody test was higher than in RT-PCR detection. In RT-PCR detection, the positive ratio was 65.91%, 71.15%, and 67.57% in moderate, severe, and critical cases, respectively. Whereas, the positive ratio of IgM/IgG antibody detection in patients was 79.55%/93.18%, 82.69%/100%, and 72.97%/97.30% in moderate, severe, and critical cases, respectively. Moreover, the concentrations of antibodies were also measured in three subgroups. ConclusionThe IgM-IgG antibodies-based test exhibited a comparative superiority to the NAT for COVID-19 diagnosis, which provides an effective complement to the false negative results from NAT for SARS-CoV-2 infection diagnosis.
ABSTRACT
Objective To investigate the differences of kinesin family member 4 (KIF4A) expression between hepatic carcinoma and adjacent tissue in patients with chronic hepatitis B virus (HBV) infection,and to understand the effect of HBV on the expression of KIF4A.Methods Reverse transcriptase-polymerase chain reaction and Western blot were used to measure the expression of KIF4A in hepatic carcinoma and adjacent tissues. HepG2 cells were co-transfected with KIF4A promoter containing the luciferase gene and HBV infectious clone pHBV1.3,and luciferase activity was measured.Expression of KIF4A in HepG2 cells was measured after tranfected with different doses of pHBV1.3.The student's t-test was used for statistic analysis.Results Expression of KIF4A was much higher in hepatic carcinoma than that in adjacent tissues.HBV enhanced KIF4 A gene promoter activity and the luciferase activities were increased as the concentration of pHBV1.3 increased ( 0,0.2,0.4,0.6 and0.8 μg/mL),which were (126.8± 13.4),(219.8±16.7),(387.6±21.5),(586.5 ± 228.9 ) and (657.6 ± 35.5 ) RUL/μg protein,respectively,while the luciferase activities were (123.6± 13.8),(131.8± 14.6),(129.7-13.5),(135.3± 13.4) and (127.1± 12.7) RUL/μg protein,respectively with different doses of control plasmids transfected,and statistical analysis showed significant difference between them (t=4.875,P=0.006).And HBV upregulated KIF4A mRNA and protein expressions in HepG2 cells in a concentration-dependent manner.Conclusion Expression of KIF4A is enhanced in hepatic carcinoma and HBV can upregulate KIF4A expression.
